



Atty. Dkt. No. 043739-0141  
App. Ser. No. 09/980,049

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Policky et al.

Title: HUMAN CYSTEINYL  
LEUKOTRIENE RECEPTORS  
(as amended)

Appl. No.: 09/980,049

Filing Date: 11/28/2001

Examiner: Ulm, John D.

Art Unit: 1646

<b>CERTIFICATE OF EXPRESS MAILING</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
EV 593167083 US (Express Mail Label Number)	July 13, 2005 (Date of Deposit)
Deborah A. Kocorowski (Printed Name)	
(Signature)	

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.56**

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. § 1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 C.F.R. § 1.97 and § 1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

07/15/2005 NNGUYEN1 00000001 09980049

02 FC:1806

180.00 OP

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 C.F.R. § 1.97(c), before the mailing date of either a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in the application.

**RELEVANCE OF EACH DOCUMENT**

Certain documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding PCT International Application (PCT/US01/10436). A copy of the PCT International Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the cited foreign-language document (WO 01/19986) has not been provided. The abstract of WO 01/19986 indicates that the application relates to “[a] cDNA encoding a novel LTC4 receptor.” The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 C.F.R. § 1.98 and M.P.E.P. § 609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with M.P.E.P. § 609.

**FEE**

A fee in connection with submission of an Information Disclosure Statement under 37 C.F.R. § 1.97(c) in the amount of \$180.00 in accordance with 37 C.F.R. § 1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 7/13/05

By M. Scott McBride

FOLEY & LARDNER LLP  
Customer Number: 22428

M. Scott McBride  
Attorney for Applicants  
Registration No. 52,008  
Telephone: (414) 297-5529  
Facsimile: (414) 297-4900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: July 13, 2005

(use as many sheets as necessary)

Sheet

1

of 1

## Complete if Known

Application Number	09/980,049
Filing Date	11/28/2001
First Named Inventor	Jennifer L. Policky
Group Art Unit	1646
Examiner Name	Ulm, John D.
Attorney Docket Number	043739-0141

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
A1	U.S. 60/199,084 (filed Apr-20-00)					

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
A2	WO	01/19986		A1	YAMANOUCHI PHARMA.	Mar-22-2001	SEQ ID NOs 1 & 2	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
A3	PCT International Search Report, based on International Application No. PCT/US01/10436, date of mailing of the International Search Report 05-07-2002 (4 pages).							
A4	DATABASE EMBL [Online] DUNN, M., "Human DNA sequence from clone RP11-108P5 on chromosome 13q14.12-21.1; contains the gene for cysteinyl leukotriene CysLT2 receptor", XP002187243, Accession AL137118 (nucleotides 103990-105030), 01-22-2000 (61 pages).							
A5	HEISE et al., "Characterization of the Human Cysteinyl Leukotriene 2 Receptor", <u>The Journal of Biological Chemistry</u> , Vol. 275, No. 39, 09-29-2000 (pgs. 30531-30536).							
A6	Synopsis of Application of Written Description Guidelines, undated (66 pages).							

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.